AbbVie and Calibr expanded their strategic collaboration to advance several innovative preclinical and early-stage assets across AbbVie’s core therapeutic areas including immunology, oncology, neuroscience, and other areas of interest. The partnership with AbbVie and Scripps Research was formed in 2019 to develop a broad range of potential new therapeutics.

In addition to programs initially named in the collaboration from preclinical to IND stages of development, Calibr will present a certain number of new discovery targets and preclinical assets of mutual interest for option considerations.

AbbVie will provide Calibr with research option payments over the course of five years to obtain a first-exclusive option to develop and commercialize candidates arising from the independent preclinical research conducted by Calibr. Should AbbVie exercise its option to a specific program, Calibr is eligible to receive additional payments, including option exercise fees, success-based development and commercial milestones, as well as royalties.

“We’ve made significant progress to advance rapidly many preclinical and clinical development programs across small molecule, biologics and CAR-T modalities,” said Thomas Hudson, senior vice president, research and development, chief scientific officer, AbbVie. “Working together with Calibr, AbbVie is excited to explore and further develop the potential of novel technologies and new clinical indications to bring breakthrough medicines to patients.”

“AbbVie has been a trusted partner to Scripps Research for many years, as proven by our successful ongoing R&D collaborations spanning numerous disease areas that have yielded four clinical stage programs,” said Peter Schultz, President, and CEO of Scripps Research and Calibr. “This expansion represents an important step forward in our mission of translating scientific insights and discoveries into innovative, clinically validated drugs, and we believe it is a model for biomedical industry-nonprofit R&D partnerships.”